Logo.jpg
Endonovo Targets Dept. of Defense, VA & Federal Contracts
January 03, 2023 09:09 ET | Endonovo Therapeutics, Inc.
Los Angeles, CA, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) announced the advancement of its aggressive “Go to Market” strategy for expansion of SofPulse® medical...
Logo.jpg
Endonovo Announces Advancement of International “Go to Market” Initiative
December 19, 2022 09:09 ET | Endonovo Therapeutics, Inc.
Los Angeles, CA, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) today announced an aggressive initiative to introduce and develop the sales and benefits of SofPulse®...
Logo.jpg
Endonovo Announces Plans for Spin-off of Medical IP and Assets
December 15, 2022 09:07 ET | Endonovo Therapeutics, Inc.
New Company To Be Formed for SofPulse® Medical Device Line Los Angeles, CA, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) today announced plans to affect a...
Logo.jpg
Endonovo Launches Telehealth Initiative
December 13, 2022 09:11 ET | Endonovo Therapeutics, Inc.
Expands Patient Education, Access to Non-Opioid Options for Pain Management Los Angeles, CA, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) today announced the...
Logo.jpg
Endonovo Names Ira Weisberg President to Guide Global Medical Expansion
November 30, 2022 09:07 ET | Endonovo Therapeutics, Inc.
Los Angeles, CA, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) today named Ira Weisberg as President and Chief Commercial Officer of its Medical Division. “Ira will...
Logo.jpg
ENDONOVO ANNOUNCES PLAN TO EXPLORE STRATEGIC ALTERNATIVES FOR ITS SOFPULSE® MEDICAL DEVICE ASSETS
November 17, 2022 09:07 ET | Endonovo Therapeutics, Inc.
Los Angeles, CA, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) today announced plans to explore strategic alternatives to maximize the shareholder value potential of...
Logo.jpg
Endonovo Therapeutics Issues Corporate Update
November 07, 2022 09:07 ET | Endonovo Therapeutics, Inc.
Highlights its previously-announced “Build Up Strategy” of acquiring complementary specialty service providers in the construction industry  Los Angeles, CA, Nov. 07, 2022 (GLOBE NEWSWIRE) --...
Logo.jpg
Endonovo Therapeutics Signs Definitive Asset Purchase Agreement to Acquire A Highly Profitable Texas Concrete Construction Company
September 27, 2022 13:52 ET | Endonovo Therapeutics, Inc.
Los Angeles, CA., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics Inc. (OTCQB: ENDV) and Western Star Concrete LLC, a highly profitable Texas concrete construction company located in the...
Logo.jpg
Endonovo Therapeutics Releases Comparative Analysis Demonstrating
July 28, 2022 09:08 ET | Endonovo Therapeutics, Inc.
More Effective SofPulse® Results Compared With Bioelectronics RecoveryRx® Los Angeles, CA, July 28, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics Inc. (OTCQB:ENDV) today released superior...
Logo.jpg
Endonovo Therapeutics Releases A Comparative Analysis Addressing Limitations Of Non-Opioid Pharmaceutical Interventions on the Reduction of Opioid/Narcotic Use For Post-Surgical Pain Management
July 21, 2022 11:30 ET | Endonovo Therapeutics, Inc.
Los Angeles, CA, July 21, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics Inc. (OTCQB:ENDV) today released a comparative analysis detailing how its SofPulse® medical device out-performed all...